A groundbreaking observational study is set to investigate the real-world efficacy of MDMA-assisted therapy through Health Canada’s Special Access Programme (SAP).
Awakn Life Sciences recently announced the completion of its feasibility study for its proprietary formulation of MDMA using Catalent’s Zydis® orally disintegrating tablet (ODT) technology.
New research has revealed that MDMA and methamphetamine deepen personal connections following guided conversations, and suggests different mechanisms for how these drugs produce feelings of closeness.
MAPS PBC has published anticipated results from its Phase 3b study that could bring MDMA-assisted therapy closer to Food and Drug Administration (FDA) approval by 2024...
PharmAla Biotech Holdings has announced that it has issued a shipment of its GMP LaNeo MDMA to Mind Medicine Australia.
With an explosion in research looking at psychedelic therapy for a number of mental health conditions, FDA approval for MDMA-assisted psychotherapy for PTSD is anticipated for...
Authorised psychiatrists are now able to prescribe MDMA and psilocybin for PTSD and treatment-resistant depression, respectively, from 1 July.
The high of MDMA (a.k.a.
Filament Health and PharmAla Biotech Holdings Inc.
The Dutch Parliament has established an independent State Commission to research the legal status of MDMA and provide advice on its medical use.